Table of Content



1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17

2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36

3 Segmentation of North America Market by Category 41
3.1 Market Overview by Category 41
3.2 Pharmaceutical Industry 43
3.3 Biopharmaceutical Industry 44

4 Segmentation of North America Market by Product 45
4.1 Market Overview by Product 45
4.2 Active Pharmaceutical Ingredients (API) 47
4.2.1 Branded API Manufacturing 48
4.2.2 Generic API Manufacturing 49
4.3 Finished Dosage Formulations (FDF) 50
4.3.1 Solid Dosage 52
4.3.2 Oral Liquids 53
4.3.3 Parenteral/Injectables 54
4.3.4 Other FDFs 55
4.4 Secondary Packaging 56

5 Segmentation of North America Market by Phase 57
5.1 Market Overview by Phase 57
5.2 Clinical Manufacturing 59
5.3 Commercial Manufacturing 60

6 Segmentation of North America Market by Type 61
6.1 Market Overview by Type 61
6.2 Sterile Products 63
6.3 Non-Sterile Products 64

7 Segmentation of North America Market by Therapeutic Application 65
7.1 Market Overview by Therapeutic Application 65
7.2 Infectious Diseases 67
7.3 Oncology 68
7.4 Metabolic Disorders 69
7.5 Cardiovascular Disorders 70
7.6 Central Nervous System 71
7.7 Pulmonary Disorders 72
7.8 Gastrointestinal Disorders 73
7.9 Other Therapeutic Applications 74

8 North America Market 2019-2030 by Country 75
8.1 Overview of North America Market 75
8.2 U.S. 78
8.3 Canada 82
8.4 Mexico 84

9 Competitive Landscape 86
9.1 Overview of Key Vendors 86
9.2 New Product Launch, Partnership, Investment, and M&A 90
9.3 Company Profiles 91
Aenova Group 91
Baxter BioPharma Solutions 93
Boehringer Ingelheim 94
Catalent Inc. 95
Famar S.A. 96
Hospira, Inc. 97
Jubilant Life Sciences Ltd. 98
Lonza Group 99
Patheon Inc. 100
Pfizer CentreSource 101
Recipharm AB 102
Vetter Pharma International GmbH 103

10 Investing in North America Market: Risk Assessment and Management 104
10.1 Risk Evaluation of North America Market 104
10.2 Critical Success Factors (CSFs) 107
Related Reports and Products 110



List of Figures


Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical Contract Manufacturing Market 26
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical Contract Manufacturing Market 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical Contract Manufacturing Market 36
Figure 11. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue 42
Figure 12. North America Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%) 42
Figure 13. North America Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, $ bn 43
Figure 14. North America Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, $ bn 44
Figure 15. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue 46
Figure 16. North America Addressable Market Cap in 2020-2030 by Product, Value ($ bn) and Share (%) 46
Figure 17. North America Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn 47
Figure 18. North America Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, $ bn 48
Figure 19. North America Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, $ bn 49
Figure 20. North America Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn 50
Figure 21. North America Pharmaceutical Contract Manufacturing Market: Solid Dosage, 2019-2030, $ bn 52
Figure 22. North America Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, $ bn 53
Figure 23. North America Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, $ bn 54
Figure 24. North America Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, $ bn 55
Figure 25. North America Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, $ bn 56
Figure 26. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue 58
Figure 27. North America Addressable Market Cap in 2020-2030 by Phase, Value ($ bn) and Share (%) 58
Figure 28. North America Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, $ bn 59
Figure 29. North America Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, $ bn 60
Figure 30. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue 62
Figure 31. North America Addressable Market Cap in 2020-2030 by Type, Value ($ bn) and Share (%) 62
Figure 32. North America Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, $ bn 63
Figure 33. North America Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, $ bn 64
Figure 34. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue 66
Figure 35. North America Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 66
Figure 36. North America Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, $ bn 67
Figure 37. North America Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, $ bn 68
Figure 38. North America Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, $ bn 69
Figure 39. North America Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, $ bn 70
Figure 40. North America Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, $ bn 71
Figure 41. North America Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, $ bn 72
Figure 42. North America Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, $ bn 73
Figure 43. North America Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, $ bn 74
Figure 44. Breakdown of North America Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue 76
Figure 45. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 77
Figure 46. U.S. Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn 79
Figure 47. Canada Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn 82
Figure 48. Pharmaceutical Contract Manufacturing Market in Mexico, 2015-2030, $ bn 84
Figure 49. Growth Stage of North America Pharmaceutical Contract Manufacturing Industry over the Forecast Period 86


List of Tables


Table 1. Snapshot of North America Pharmaceutical Contract Manufacturing Market, 2019-2030 18
Table 2. Growth Rate of World Real GDP, 2017-2021 22
Table 3. Main Product Trends and Market Opportunities in North America Pharmaceutical Contract Manufacturing Market 32
Table 4. North America Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, $ bn 41
Table 5. North America Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn 45
Table 6. North America Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn 47
Table 7. North America Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn 51
Table 8. North America Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn 57
Table 9. North America Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, $ bn 61
Table 10. North America Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn 65
Table 11. North America Pharmaceutical Contract Manufacturing Market by Country, 2019-2030, $ bn 76
Table 12. U.S. Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn 80
Table 13. U.S. Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn 80
Table 14. U.S. Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn 80
Table 15. Canada Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn 83
Table 16. Canada Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn 83
Table 17. Canada Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn 83
Table 18. Mexico Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn 85
Table 19. Mexico Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn 85
Table 20. Mexico Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn 85
Table 21. Breakdown of North America Market by Key Vendor, 2019, % 88
Table 22. Aenova Group: Company Snapshot 91
Table 23. Aenova Group: Business Segmentation 91
Table 24. Aenova Group: Product Portfolio 92
Table 25. Aenova Group: Revenue, 2016-2018, $ bn 92
Table 26. Aenova Group: Recent Developments 92
Table 27. Risk Evaluation for Investing in North America Market, 2019-2030 105
Table 28. Critical Success Factors and Key Takeaways 108